^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BIRC2 amplification

i
Other names: BIRC2, Baculoviral IAP Repeat Containing 2, C-IAP1, RNF48, MIHB, Baculoviral IAP Repeat-Containing Protein, RING-Type E3 Ubiquitin Transferase BIRC2, TNFR2-TRAF-Signaling Complex Protein 2, NFR2-TRAF Signalling Complex Protein, Cellular Inhibitor Of Apoptosis 1, Inhibitor Of Apoptosis Protein 2, RING Finger Protein 48, Apoptosis Inhibitor 1, IAP Homolog B, Hiap-2, HIAP2, CIAP1, API1, Baculoviral IAP Repeat-Containing 2, HIAP-2, IAP-2
Entrez ID:
Related biomarkers:
10ms
Insights into the mechanisms and structure of breakage-fusion-bridge cycles in cervical cancer using long-read sequencing. (PubMed, Am J Hum Genet)
This suggests that individuals with cervical cancer and YAP1-BIRC3-BIRC2 amplification, especially those of African ancestry, might benefit from targeted therapy. In summary, we uncovered valuable insights into the mechanisms and consequences of BFB cycles in cervical cancer using long-read sequencing.
Journal
|
BIRC3 (Baculoviral IAP repeat containing 3) • YAP1 (Yes associated protein 1) • BIRC2 (Baculoviral IAP Repeat Containing 2)
|
BIRC2 amplification
over2years
BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia. (PubMed, Sci Rep)
We then found the drug AZD5582, a known small molecule inhibitor of BIRC2-3, to selectively kill FA tumor cells that overexpressed BIRC2-3...Our data indicate that 11q22.2 amplifications are relatively common oncogenic events in FA-HNSCCs, as holds for non FA-HNSCC. Therefore, chemotherapeutic inhibition of overexpressed BIRC2-3 may provide the basis for an approach to develop a clinically realistic treatment of FA-HNSCCs that carry 11q22.2 amplifications.
Clinical • Journal
|
BIRC3 (Baculoviral IAP repeat containing 3) • YAP1 (Yes associated protein 1) • BIRC2 (Baculoviral IAP Repeat Containing 2)
|
BIRC2 amplification
|
AZD5582